About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

378040 studies
in
220 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/14/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/14/2021.

One Research on Improving Cognitive Impairment Caused by Hypertension

Clinicaltrials.gov identifier NCT03943420

Recruitment Status Recruiting

First Posted May 9, 2019

Last update posted May 9, 2019

Study Description

Brief summary:

Using the therapy of early intervention with Qianyang Yuyin Granules to improve cognitive impairment caused by hypertension.

  • Condition or Disease:Hypertension
  • Intervention/Treatment:
  • Phase: N/A
Detailed Description

Using the therapy of early intervention with Qianyang Yuyin Granules to improve cognitive impairment caused by hypertension. The investigators designed a multi-center randomized controlled clinical trial to study the security and effectiveness of this therapy.

Study Design
  • Study Type: Observational [Patient Registry]
  • Estimated Enrollment: 144 participants
  • Observational Model: Case-Control
  • Time Perspective: Prospective
  • Official Title: One Research on Application of Key Technologies About Improving Cognitive Impairment Caused by Hypertension With the Therapy of Early Intervention With Qianyang Yuyin Granules
  • Actual Study Start Date: December 2018
  • Estimated Primary Completion Date: December 2020
  • Estimated Study Completion Date: December 2020
Outcome Measures
  • Primary Outcome Measures: 1. Changes of brain image [ Time Frame: 24 weeks ]
    Measure and record the volume changes of diseased alba, the micro-structure changes of alba fasciculus by MRI to see if the therapy effect or not.
  • 2. Measure and assess the changes of VaDAS-cog ( Vascular Dementia Assessment Scale cognitive subscale ) among time points [ Time Frame: 12 weeks, 24 weeks, 48 weeks ]
    Measure and record with VaDAS-cog
  • Secondary Outcome Measures: 1. Measure and assess the changes of MMSE ( Mini-mental State Examination ) among time points [ Time Frame: 12 weeks, 24 weeks, 48 weeks ]
    Measure and record with MMSE
  • 2. Measure and assess the changes of ADL ( Activity of Daily Living ) among time points [ Time Frame: 12 weeks, 24 weeks, 48 weeks ]
    Measure and record with ADL
  • 3. Measure and assess the changes of CDR ( Clinical Dementia Rating ) among time points [ Time Frame: 12 weeks, 24 weeks, 48 weeks ]
    Measure and record with CDR
  • 4. Incidence rate of outcome event [ Time Frame: 24 weeks ]
    Record the outcome event and analyse the incidence rate
  • 5. Therapeutic effect [ Time Frame: 24 weeks ]
    Measure and record patients' systolic and diastolic blood pressure and analyse related data
  • 6. Metabonomics [ Time Frame: 24 weeks ]
    Measure and record the metabonomics ( Trx & TrxR ) index
  • Biospecimen Retention: Samples With DNA

    Blood sample; Urine sample.

Eligibility Criteria
  • Ages Eligible for Study: 55 to 75 Years (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
  • Sampling Method: Probability Sample
  • Study Population: Patients with cognitive impairment caused by hypertension.
Criteria

Inclusion Criteria:

- Aged 55 to 75 years old, male or female;

- Having a history of hypertension for more than 2 years but can maintain SBP ≤ 140 mmHg
and BDP ≤ 90 mmHg with medication;

- 21 ≤ MMSE < 26, or 14 ≤ MoCA < 26, CDR < 0.5. Bseides, the chief complaint must happen after having hypertension; - Meet TCM Syndrome Differentiation Standard:according to the Guidelines for the Clinical Research of Chinese Medicine New Drugs ( published by China Medical Science Press ) :Overabundant liver-fire type:dizziness and headache, both face and eyes are red, dry mouth and bitter taste in mouth, red tongue with yellowish coating, wire and frequent pulse. Yin deficiency and yang hyperactivity type: dizziness and headache, Tinnitus and forgetfulness, sphoria with feverish sensation in chest & palms & soles, palpitation and insomnia, red tongue & thin white or less coating, wiry weak and numbered pulse; - CTMRI hint: leukoaraiosis and no sign of Cerebral infarction; - Patients or the guardian hold the right opinions over the research and are willing to obey researcher's orders; - Having a certain degree of education (being able to read simple newspapers in the past); - Patients agree to sign informed consent。 Exclusion Criteria: - Secondary hypertension; - Taking certain kinds of antihypertensive drugs which may damage brain cognitive function; - Diagnosed as depression or other mental disorders according to DSM-IV; - Diagnosed as vascular dementia according to diagnostic criteria, CDR ≥ 0.5; alzheimer disease or dementia caused by some other reasons (including mixed dementia according to diagnostic criteria for VCI); cognitive impairment due to head injury。 - Suffering from certain kinds of diseases which may interfere the assessment of cognitive function, including those who are diagnosed as alcoholics and drugs or psychotropic medicine abusers during the last 5 years according to DSM-IV; - Accompanied with severe neurological function disorder; - Asthma, chronic severe primary cardiovascular disease, liver lesion, hematological lesions, lung diseases, diabetes or other severe diseases may influence the patients' survival such as cancer or AIDS; - Other: Such as poor compliance, or can not attend the follow-up visit in time for some reasons; - Taking the same kind of medicine during the last 30 days which may influence the trial; - Is participating in another clinical study; - Not up to TCM Syndrome Differentiation Standard。

Contacts and Locations
Contacts

Contact: Cheng Chang, PhD +8613851821996 chch1967@163.com

Locations

China, Jiangsu
Jiangsu Province Hospital of Chinese Medcine
Nanjing

Sponsors and Collaborators

Jiangsu Famous Medical Technology Co., Ltd.

More Information
  • Responsible Party: Jiangsu Famous Medical Technology Co., Ltd.
  • ClinicalTrials.gov Identifier: NCT03943420 History of Changes
  • Other Study ID Numbers: BE2017770
  • First Posted: May 9, 2019 Key Record Dates
  • Last Update Posted: May 9, 2019
  • Last Verified: April 2019
  • Individual Participant
    Data (IPD) Sharing
    Statement:
  • Plan to Share IPD: Undecided
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Keywords provided by Jiangsu Famous Medical Technology Co., Ltd.: Safety
    Effectiveness
    Therapy
    Qianyang Yuyin Granules
    Cognitive impairment
    Hypertension
  • Additional relevant MeSH terms: Cognitive Dysfunction Hypertension